DOI: https://doi.org/10.30978/UTJ2018-3-4-79

Ацетилсаліцилова кислота в кардіологічній практиці: фокус на ентеротоксичність

O. Yu. Gubska, A. I. Taran, I. O. Lavrenchuk, T. S. Alyanova

Анотація


Ацетилсаліцилова кислота (АСК) є одним з найчастіше призначуваних препаратів у світі. Постійний  прийом АСК має суттєві побічні ефекти, у тому числі з боку шлунково-кишкового тракту.  В огляді, присвяченому ентеротоксичному впливу АСК, викладено сучасні погляди на застосування дезагрегантної терапії, а також висвітлено уявлення щодо частоти, патогенезу та підходів до лікування АСК-асоційованих ентеропатій.

Ключові слова


ацетилсаліцилова кислота; клопідогрель; ентеропатія; ентеротоксичність; гастропатія

Повний текст:

PDF

Посилання


Gubskaya EYu. Novyy diagnoz mikroskopicheskiy enterit: opredeleniye, sovremennyye podkhody k diagnostike, differentsial'noy diagnostike i lecheniyu. Sovremennaya gastroenterologiya. 2016;3:120-­126.

Kushnir SM. Terapevtychna efektyvnist atsetilsalitsilovoyi kysloty pry sertsevo­sudynna zakhvoryuvannyakh. Zhurn Arterialna hipertenziya. 2012;2 (22).

Shcherbatykh YeV, Kalyagin AN, Shcherbatykh AV. NPVP­assotsiirovannaya patologiya organov pishchevareniya. Sib med zhurn (Irkutsk). 2007;7:23­-27.

Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting. Canadian J Сardiol. 2011;27 (3):S1-­S59.

Bjarnason I, et al. Effect of non­steroidal anti­-inflammatory drugs on the human small intestine. Drugs. 1986;32(1):35-­41.

Bjarnason I, et al. Metronidazole reduces intestinal inflammation and blood loss in non­steroidal anti­-inflammatory drug induced enteropathy. Gut. 1992;33 (9):1204-­1208.

Bjarnason I, Hayllar J. Side effects of nonsteroidal anti­inflammatory drugs on the small and large intestine in humans. Gastroenterol. 1993;104(6):1832­-1847.

Boelsterli UА, Ramirez­Alcantara V. NSAID acyl glucuronides and enteropathy. Curr. Drug Metab. 2011;12 (3):245-­252.

Chan FKL, Lau JYW. Peptic ulcer disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA. Elsevier Saunders; 2016.

Chen WC, Lin KH, Huang YT, et al. The risk of lower gastrointestinal bleeding in low­-dose aspirin users. Aliment Pharmacol Ther. 1201;457(2):1542­-1550.

Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer A Decision Analysis: Technical Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). 2015 Report N 15­05229­EF­1. https://www.ncbi.nlm.nih.gov/books/NBK321651.

Endo H, et al. Characteristics of small bowel injury in symptomatic chronic low­-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44(6):544.

Endo H, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low­-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46(7):894­-905.

Endo H, et al. Incidence of small bowel injury induced by low-­dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion. 2009;79(1):44­-51.

Endo H, et al. Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-­dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? J. Gastroenterol. 2017;52(2):194-­202.

Fujimori S, et al. Prevention of nonsteroidal anti­-inflammatory drug–induced small­-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointestinal Endoscopy. 2009;69(7):1339-­1346.

Iwamoto J, et al. Small­-bowel mucosal injuries in low­-dose aspirin users with obscure gastrointestinal bleeding. World J Gastroenterol. 2014;20(36):13133-­13138. doi:10.3748/wjg.v20.i36.13133.

Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969;54(2):237.

Lambert M. AHA/ASA guidelines on prevention of recurrent stroke. Am Fam Physician. 2011;83(8):993­-1001.

Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID­-related ulcer complications. Am J Gastroenterol. 2009;104(3):7-28.

Leung JW, et al. Expression of bacterial β-­glucuronidase in human bile: an in vitro study. Gastrointestinal Endoscopy. 2001;54(3):346­-350.

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082­1115. doi:10.1016/j.jacc.2016.03.513.

Maiden L, et al. Long­term effects of nonsteroidal anti­inflammatory drugs and cyclooxygenase­-2 selective agents on the small bowel: a cross­-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5(9):1040­-1045.

McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Failure. 2012;14(8):803­-869.

Mizukami K, et al. Aspirin­induced small bowel injuries and the preventive effect of rebamipide. World J. Gastroenterology. 2011;17 (46):5117-­5122. doi: 10.3748/wjg.v17.i46.5117.

Montalto M, et al. Clinical trial: the effects of a probiotic mixture on non­steroidal anti­-inflammatory drug enteropathy­a randomized, double-­blind, cross­over, placebo­-controlled study. Aliment Pharmacol Ther. 2010;32(2):209-­214. doi:10.1111/j.1365­2036.2010.04324.x.

Muraki M, et al. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non­steroidal anti­inflammatory drug users. Scand J Gastroenterol. 2014;49(3):267­273.

Otani K, et al. Microbiota Plays a Key Role in Non­-Steroidal Anti­Inflammatory Drug­-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-­28.

Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-­inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterol. 1997;112(1):109­-117.

Schmassmann A, et al. Effects of inhibition of prostaglandin endoperoxide synthase­2 in chronic gastro­intestinal ulcer models in rats. Br J Pharmacol. 1998;123(5):795-­804.

Shinomura Y. New Trends and Techniques in Gastroenterology. Digestion. 2017;95(1):5.

Shiotani A, Kamada T, Haruma K. Low­-dose aspirin-­induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43(8):581­-588.

Shiotani A, et al. Randomized, double-­blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-­dose enteric­coated aspirin. Low­-dose aspirin­-induced small bowel damage. Scand J Gastroenterol. 2010;45(3):292­-298.

Srinivasan A, De Cruz P. А practical approach to the clinical management of NSAID enteropathy. Scand J Gastroenterol. 2017;52(9):941­-947. doi10.1080/00365521.2017.1335769.

Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Ann Intern Med. 2009;150(6):379­-386.

Truong C. Low-­dose acetyl-salicylic acid for primary prevention of cardiovascular disease. Can Fam Physician. 2015;61(11):971-975.

Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti­-inflammatory drug­-enteropathy. World J Gastroenterol. 2013;19(12):1861­-1876. doi:10.3748/wjg.v19.i12.1861.

Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012;165(1):67­-74.

Watanabe T, et al. A multi-center, randomized, double­-blind, placebo­-controlled trial of high­-dose rebamipide treatment for low­dose aspirin-­induced moderate-­to­-severe small intestinal damage. PloS One. 2015;10(4):e0122330.

Watanabe T, et al. Mitochondrial disorders in NSAIDs­-induced small bowel injury. J Clin Biochem Nutr. 2011;48(2):117-­121.




© Український терапевтичний журнал, 2019
© ПП «ІНПОЛ ЛТМ», 2019